Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2005, for Kimberly-Clark Corporation. The company operates three global business segments: Personal Care, Consumer Tissue, and Business-to-Business. The reporting period follows the November 2004 spin-off of Neenah Paper, Inc., which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Q2 2005 | Q2 2004 | YTD 2005 | YTD 2004 |
|---|---|---|---|---|
| Net Sales ($ millions) | $3,987.1 | $3,687.3 | $7,892.9 | $7,398.8 |
| Operating Profit ($ millions) | $636.2 | $624.7 | $1,273.8 | $1,248.1 |
| Net Income ($ millions) | $421.8 | $454.3 | $871.9 | $913.6 |
| Diluted EPS ($) | $0.88 | $0.90 | $1.81 | $1.81 |
| Cash from Operations ($ millions, YTD) | $1,082.7 | $1,323.2 | - | - |
| Total Debt & Preferred Securities ($ millions) | $4,172.5 | - | - | - |
| Cash and Equivalents ($ millions) | $466.1 | - | - | - |
Note: Total Debt includes $1,126.6 million current and $2,306.1 million long-term debt, plus $739.8 million preferred securities of subsidiary.
Material Changes vs. Prior Period
- Revenue Growth: Q2 Net Sales increased 8.1% year-over-year, driven by a 5% volume increase, 3% favorable currency impact, and 1% product mix improvement. This growth offset a 1% decline due to the prior year's pulp operations divestiture.
- Profitability: Operating profit rose 1.8% in Q2. However, Net Income declined 7.2% primarily due to a higher effective tax rate (25.6% vs. 21.5%) caused by the repatriation of foreign earnings under the American Jobs Creation Act.
- Segment Performance:
- Personal Care: Sales up 7.4%; Operating profit down 2.5% due to lower net selling prices and raw material inflation.
- Consumer Tissue: Sales up 12.9%; Operating profit up 12.1% driven by volume and price increases.
- Business-to-Business: Sales down 3.5% (impacted by pulp divestiture); Operating profit down 7.6%.
- Cash Flow: Cash provided by operations for the first six months decreased 18.2% to $1.08 billion, reflecting higher working capital investment and lower net income.
Guidance, Outlook, and Risks
- Competitive Improvement Initiatives: Management announced a multi-year program to streamline operations and invest in growth. This is expected to result in cumulative pre-tax charges of $900 million to $1.1 billion through 2008, with annual pre-tax savings of $300-$350 million by 2009.
- Capital Allocation:
- Share Repurchases: The company raised its 2005 repurchase target to $1.5 billion (from $1 billion). $501 million was spent in the first six months.
- Capital Spending: Reduced 2005 target to $650-$700 million (from $800 million).
- Tax Contingency: The company is evaluating the repatriation of an additional $400 million in foreign earnings, which could result in up to $20 million in additional tax expense.
- Risks: Significant inflationary pressures on raw materials (resin, fiber, energy) and intense price competition in key markets. The company expects to incur significant charges in Q3 and Q4 related to the new cost reduction initiatives.
Investor Verification Checklist
- Verify the impact of the American Jobs Creation Act on future tax provisions and potential additional repatriation charges.
- Monitor the execution of the Competitive Improvement Initiatives, specifically the timing of the $900M-$1.1B in charges and the realization of cost savings.
- Assess the sustainability of volume growth in Personal Care and Consumer Tissue segments amidst ongoing price competition and inflation.
- Review the synthetic fuel partnership losses ($47.9M in Q2) and the associated tax credit benefits, noting the phase-out risks if oil prices exceed specific thresholds.
- Confirm the progress of the share repurchase program against the new $1.5 billion target and its impact on diluted EPS.